HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ETH 615

leukotriene B4 and interleukin-8 antagonist; structure in first source

Also Known As:

ETH-615

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - ETH 615: 1

Experts

1.	Lambert, Ian Henry: 1 article (12/2014)
2.	Sørensen, Belinda Halling: 1 article (12/2014)
3.	Thorsteinsdottir, Unnur Arna: 1 article (12/2014)

Related Diseases

1.

Ovarian Neoplasms (Ovarian Cancer)

12/15/2014 - "Here we find that volume-sensitive taurine release in cisplatin-sensitive [wild-type (WT)] human ovarian cancer A2780 cells is reduced in the presence of the phospholipase A2 inhibitor bromenol lactone, the 5-lipoxygenase (5-LO) inhibitor ETH 615-139, and the cysteine leukotriene receptor 1 (CysLT1) antagonist zafirlukast and impaired by the anion channel blocker DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonate). "

Related Drugs and Biologics

1.	Leukotriene Receptors (Leukotriene Receptor)
2.	4,4'- Diisothiocyanostilbene- 2,2'- Disulfonic Acid (DIDS)
3.	Taurine
4.	Lactones
5.	Cysteine (L-Cysteine)
6.	Cisplatin (Platino)
7.	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)
8.	Anions
9.	PLIalpha
10.	zafirlukast (Accolate)